Himaja Dutt Chigurupati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Himaja Dutt Chigurupati has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Sivaram Neppala
Division of Cardiology The University of Texas Health Sciences Center San Antonio Texas USA
12 shared publications - Muhammad Abdullah Naveed
Department of Cardiology, Dow Medical College Dow University of Health Sciences Karachi Pakistan
9 shared publications - Bazil Azeem
Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan
6 shared publications - Ahila Ali
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
5 shared publications - Mushood Ahmed
Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan
3 shared publications - Faizan Ahmed
Department of Internal Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (6)
Rising Atrial Fibrillation Mortality Trends in Hypertensive Patients Aged 25 and Older: A CDC Wonder Database Analysis
Background: Atrial fibrillation (AF) is a leading arrhythmia contributing to cardiovascular mortality, particularly among individuals with Hypertension (HTN), yet long‐term trends and disparities remain underexplored. We analyzed national patterns and sociodemographic differences in AF‐related mortality among US adults aged 25 years or older from 1999 to 2023. Methods: We used CDC WONDER mortality data (1999–2023) to analyze AF‐related deaths among US adults aged ≥ 25 with HTN. Age‐adjusted mortality rates (AAMR) per 100 000 and average annual percent changes (AAPC) were calculated using Joinpoint regression to assess overall and subgroup‐specific trends. Results: AF accounted for 1 108 265 deaths among adults with HTN, with AAMRs increasing from 3.8 in 1999 to 35.9 in 2023 (AAPC: 6.03%). The sharpest rise occurred from 2018 to 2021, with an APC of 14.57%, coinciding with the COVID‐19 pandemic. Men had higher AAMRs than women (20.5 vs. 17.1). Racial disparities were evident, with non‐Hispanic Whites having the highest AAMR (20.1), followed by non‐Hispanic Blacks (15.1), Hispanics (11.3), and non‐Hispanic Others (10.7). Regional variation showed that the West had the highest AAMR (20.8), while Vermont recorded the highest state rate (28.7), and Nevada had the lowest (11.4). Rural areas exhibited higher mortality rates than urban areas (17.8 vs. 16.1), with rural AAMRs increasing at a faster rate (AAPC: 10.61%). Conclusion: The rising burden of AF‐related mortality in hypertensive patients, especially among men, non‐Hispanic Whites, and rural populations, signals a critical public health concern. Immediate, equity‐focused interventions are needed to mitigate disparities and reduce AF‐related mortality across the United States.
- 18 November 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (6)
Open AccessRising Atrial Fibrillation Mortality Trends in Hypertensive Patients Aged 25 and Older: A CDC Wonder Database Analysis
Background: Atrial fibrillation (AF) is a leading arrhythmia contributing to cardiovascular mortality, particularly among individuals with Hypertension (HTN), yet long‐term trends and disparities remain underexplored. We analyzed national patterns and sociodemographic differences in AF‐related mortality among US adults aged 25 years or older from 1999 to 2023. Methods: We used CDC WONDER mortality data (1999–2023) to analyze AF‐related deaths among US adults aged ≥ 25 with HTN. Age‐adjusted mortality rates (AAMR) per 100 000 and average annual percent changes (AAPC) were calculated using Joinpoint regression to assess overall and subgroup‐specific trends. Results: AF accounted for 1 108 265 deaths among adults with HTN, with AAMRs increasing from 3.8 in 1999 to 35.9 in 2023 (AAPC: 6.03%). The sharpest rise occurred from 2018 to 2021, with an APC of 14.57%, coinciding with the COVID‐19 pandemic. Men had higher AAMRs than women (20.5 vs. 17.1). Racial disparities were evident, with non‐Hispanic Whites having the highest AAMR (20.1), followed by non‐Hispanic Blacks (15.1), Hispanics (11.3), and non‐Hispanic Others (10.7). Regional variation showed that the West had the highest AAMR (20.8), while Vermont recorded the highest state rate (28.7), and Nevada had the lowest (11.4). Rural areas exhibited higher mortality rates than urban areas (17.8 vs. 16.1), with rural AAMRs increasing at a faster rate (AAPC: 10.61%). Conclusion: The rising burden of AF‐related mortality in hypertensive patients, especially among men, non‐Hispanic Whites, and rural populations, signals a critical public health concern. Immediate, equity‐focused interventions are needed to mitigate disparities and reduce AF‐related mortality across the United States.
- 18 August 2026
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (5) , e453-e460
Sotatercept in Patients With Pulmonary Arterial Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials
Was not provided for this article.
- 18 August 2026
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (5) , e453-e460
Sotatercept in Patients With Pulmonary Arterial Hypertension: An Updated Meta-Analysis of Randomized Controlled Trials
Was not provided for this article.
- 22 February 2026
- Published by Wiley in European Journal of Haematology
- Vol. 116 (6) , 863-872
Reduced‐ Versus Extended‐Dose Anticoagulation for Venous Thromboembolism in Patients With and Without Cancer: A Systematic Review and Meta‐Analysis
Background: Extended‐duration anticoagulation reduces recurrent venous thromboembolism (VTE) in cancer and non‐cancer patients. Reduced‐dose direct oral anticoagulants (DOACs) may be safer if they match efficacy with less bleeding risk. We conducted a systematic review and meta‐analysis of trials comparing reduced‐dose and extended‐dose DOACs. Methods: Randomized controlled trials comparing reduced‐dose with extended‐dose anticoagulation for secondary VTE prevention were systematically reviewed. Primary outcomes included recurrent symptomatic VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT). Secondary outcomes included bleeding, adverse events, and all‐cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Subgroup and leave‐one‐out sensitivity analyses explored heterogeneity and robustness. All analyses were conducted in R (version 4.3.1). Results: Six RCTs ( n = 9382) were included. Reduced‐dose anticoagulation showed no statistically significant difference in recurrent VTE (RR 0.98, 95% CI 0.72–1.33), PE (RR 0.96, 95% CI 0.61–1.50), or DVT (RR 0.86, 95% CI 0.56–1.32) compared with extended‐dose therapy. Major bleeding was significantly reduced (RR 0.68, 95% CI 0.48–0.98), as were clinically relevant non‐major bleeding and any bleeding. All‐cause mortality did not differ significantly. Heterogeneity was low to moderate across outcomes, and sensitivity analyses confirmed the stability of results. Conclusion: Reduced‐dose anticoagulation demonstrated similar efficacy with improved safety compared with extended‐dose therapy. These findings support individualized dose reduction strategies after extended anticoagulation. Trial Registration: ClinicalTrials.gov identifier: CRD420251081952
- 22 February 2026
- Published by Wiley in European Journal of Haematology
- Vol. 116 (6) , 863-872
Reduced‐ Versus Extended‐Dose Anticoagulation for Venous Thromboembolism in Patients With and Without Cancer: A Systematic Review and Meta‐Analysis
Background: Extended‐duration anticoagulation reduces recurrent venous thromboembolism (VTE) in cancer and non‐cancer patients. Reduced‐dose direct oral anticoagulants (DOACs) may be safer if they match efficacy with less bleeding risk. We conducted a systematic review and meta‐analysis of trials comparing reduced‐dose and extended‐dose DOACs. Methods: Randomized controlled trials comparing reduced‐dose with extended‐dose anticoagulation for secondary VTE prevention were systematically reviewed. Primary outcomes included recurrent symptomatic VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT). Secondary outcomes included bleeding, adverse events, and all‐cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Subgroup and leave‐one‐out sensitivity analyses explored heterogeneity and robustness. All analyses were conducted in R (version 4.3.1). Results: Six RCTs ( n = 9382) were included. Reduced‐dose anticoagulation showed no statistically significant difference in recurrent VTE (RR 0.98, 95% CI 0.72–1.33), PE (RR 0.96, 95% CI 0.61–1.50), or DVT (RR 0.86, 95% CI 0.56–1.32) compared with extended‐dose therapy. Major bleeding was significantly reduced (RR 0.68, 95% CI 0.48–0.98), as were clinically relevant non‐major bleeding and any bleeding. All‐cause mortality did not differ significantly. Heterogeneity was low to moderate across outcomes, and sensitivity analyses confirmed the stability of results. Conclusion: Reduced‐dose anticoagulation demonstrated similar efficacy with improved safety compared with extended‐dose therapy. These findings support individualized dose reduction strategies after extended anticoagulation. Trial Registration: ClinicalTrials.gov identifier: CRD420251081952
- Open Access
- 26 January 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Temporal patterns in diabetes and sepsis mortality in older Americans: a population-based analysis
Background: Diabetes mellitus significantly elevates the risk of sepsis and exacerbates its clinical outcomes, leading to increased mortality rates. Despite the importance of this association, the demographic and geographic patterns influencing it remain inadequately understood. Methods: Utilizing data from CDC WONDER (1999–2020), we conducted an analysis of mortality trends among U.S. adults aged 65 and older, stratified by gender, race/ethnicity, and geographic region. Age-adjusted mortality rates (AAMRs) and annual percentage changes (APCs) were evaluated using the Joinpoint Regression methodology. Results: Between 1999 and 2020, there were a total of 287,738 deaths attributed to diabetes and sepsis. The AAMR decreased from 33.6 per 100,000 population in 1999 to 27.7 in 2014; however, it subsequently surged to 38.4 by 2020 (APC: 13.65). The male AAMRs reached a peak of 39.1 in 2005, declined to 31.2 in 2012, and then increased to 46.9 in 2020 (APC 12.29). Female AAMRs decreased from 32.6 in 1999 to 24.8 in 2018, before rising again to 31.9 in 2020 (APC 13.66). Among African Americans, mortality declined to 46.3 in 2019 but experienced a sharp increase to 65.7 in 2020 (APC 20.52). The Hispanic AAMR also increased during this period (APC 25.05). The southern region consistently exhibited the highest mortality rates, rising from 31.7 in 2018 to 42.5 in 2020 (APC 13.69), with notable rises observed in the Midwest (APC 14.59). All these trends were statistically significant ( p < 0.05). Furthermore, non-metropolitan areas consistently demonstrated higher mortality rates, with significant increases observed between 2018 and 2020. Conclusion: The mortality rates associated with diabetes-related sepsis have recently risen, particularly between 2018 and 2020, thereby highlighting significant health disparities. It is essential to implement targeted healthcare interventions.
- 26 January 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Open AccessTemporal patterns in diabetes and sepsis mortality in older Americans: a population-based analysis
Background: Diabetes mellitus significantly elevates the risk of sepsis and exacerbates its clinical outcomes, leading to increased mortality rates. Despite the importance of this association, the demographic and geographic patterns influencing it remain inadequately understood. Methods: Utilizing data from CDC WONDER (1999–2020), we conducted an analysis of mortality trends among U.S. adults aged 65 and older, stratified by gender, race/ethnicity, and geographic region. Age-adjusted mortality rates (AAMRs) and annual percentage changes (APCs) were evaluated using the Joinpoint Regression methodology. Results: Between 1999 and 2020, there were a total of 287,738 deaths attributed to diabetes and sepsis. The AAMR decreased from 33.6 per 100,000 population in 1999 to 27.7 in 2014; however, it subsequently surged to 38.4 by 2020 (APC: 13.65). The male AAMRs reached a peak of 39.1 in 2005, declined to 31.2 in 2012, and then increased to 46.9 in 2020 (APC 12.29). Female AAMRs decreased from 32.6 in 1999 to 24.8 in 2018, before rising again to 31.9 in 2020 (APC 13.66). Among African Americans, mortality declined to 46.3 in 2019 but experienced a sharp increase to 65.7 in 2020 (APC 20.52). The Hispanic AAMR also increased during this period (APC 25.05). The southern region consistently exhibited the highest mortality rates, rising from 31.7 in 2018 to 42.5 in 2020 (APC 13.69), with notable rises observed in the Midwest (APC 14.59). All these trends were statistically significant ( p < 0.05). Furthermore, non-metropolitan areas consistently demonstrated higher mortality rates, with significant increases observed between 2018 and 2020. Conclusion: The mortality rates associated with diabetes-related sepsis have recently risen, particularly between 2018 and 2020, thereby highlighting significant health disparities. It is essential to implement targeted healthcare interventions.
- Open Access
- 26 November 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (12) , e70211
Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia
Background: Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia. Methods: A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic. Results: Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%). Conclusion: Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.
- 26 November 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (12) , e70211
Open AccessDual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia
Background: Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia. Methods: A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic. Results: Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%). Conclusion: Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.
- Open Access
- 15 October 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (11) , 103788
Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation for Hypertrophic Cardiomyopathy
- 15 October 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (11) , 103788
Open AccessSocioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation for Hypertrophic Cardiomyopathy
- Open Access
- 14 October 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (12) , 1434-1443
Mortality Trends in Atrial Fibrillation With Cardiomyopathy Among Patients Aged 25 and Older in the United States
Background: Atrial fibrillation (AF) is a prevalent arrhythmia that frequently coexists with cardiomyopathy, leading to deteriorated cardiovascular outcomes. Analyzing the trends associated with these conditions is essential for improving prevention strategies and management practices. Methods: CDC WONDER (1999–2023) data were analyzed to assess AF with cardiomyopathy‐related mortality in patients aged ≥ 25. Using Joinpoint regression analysis, we calculated age‐adjusted mortality rates (AAMRs) per 100,000 patients and average annual percentage changes (AAPCs) to analyze mortality trends. Results: AF with cardiomyopathy is responsible for 126,377 deaths among adults aged 25 and older. Alarmingly, AAMRs have surged from 1.8 per 100,000 in 1999 to 3.0 in 2023 (AAPC: 2.11, p < 0.001). The upward trend remains pronounced, particularly between 2016 and 2021, with an annual percentage change of 6.17 ( p = 0.02). Disparities in mortality rates are striking. Men face a higher AAMR than women (3.1 vs. 1.5), and Black individuals bear the heaviest burden at 2.4, closely followed by Whites at 2.3. Regionally, Vermont stands out with the highest AAMR at 3.6, while New York reports the lowest at 1.3. Both rural and urban areas maintain equal AAMRs of 2.1, yet the increase in rural regions is particularly concerning, reflecting an AAPC of 2.44 compared to 1.78 in urban settings. Conclusion: The rising mortality rates from AF with cardiomyopathy in patients, particularly among men, Black individuals, and rural residents, demand urgent action. These concerning trends underscore a public health crisis that must be addressed.
- 14 October 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (12) , 1434-1443
Open AccessMortality Trends in Atrial Fibrillation With Cardiomyopathy Among Patients Aged 25 and Older in the United States
Background: Atrial fibrillation (AF) is a prevalent arrhythmia that frequently coexists with cardiomyopathy, leading to deteriorated cardiovascular outcomes. Analyzing the trends associated with these conditions is essential for improving prevention strategies and management practices. Methods: CDC WONDER (1999–2023) data were analyzed to assess AF with cardiomyopathy‐related mortality in patients aged ≥ 25. Using Joinpoint regression analysis, we calculated age‐adjusted mortality rates (AAMRs) per 100,000 patients and average annual percentage changes (AAPCs) to analyze mortality trends. Results: AF with cardiomyopathy is responsible for 126,377 deaths among adults aged 25 and older. Alarmingly, AAMRs have surged from 1.8 per 100,000 in 1999 to 3.0 in 2023 (AAPC: 2.11, p < 0.001). The upward trend remains pronounced, particularly between 2016 and 2021, with an annual percentage change of 6.17 ( p = 0.02). Disparities in mortality rates are striking. Men face a higher AAMR than women (3.1 vs. 1.5), and Black individuals bear the heaviest burden at 2.4, closely followed by Whites at 2.3. Regionally, Vermont stands out with the highest AAMR at 3.6, while New York reports the lowest at 1.3. Both rural and urban areas maintain equal AAMRs of 2.1, yet the increase in rural regions is particularly concerning, reflecting an AAPC of 2.44 compared to 1.78 in urban settings. Conclusion: The rising mortality rates from AF with cardiomyopathy in patients, particularly among men, Black individuals, and rural residents, demand urgent action. These concerning trends underscore a public health crisis that must be addressed.
- Open Access
- 10 October 2025
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 15 (1) , 1-13
Trends and Disparities in Stroke Mortality Among Adults with Hyperlipidemia in the United States, 1999–2023
Background Stroke is a leading cause of death in the U.S., with mortality trends influenced by hyperlipidemia, a significant risk factor for atherosclerosis and cardiovascular disease that can lead to ischemic stroke. This analysis examines stroke-related mortality in hyperlipidemia among adults aged 25 and older from 1999 to 2023. Methods A retrospective analysis of CDC WONDER investigated trends in mortality from Stroke (ICD codes: I60-I69) among Hyperlipidemia patients (ICD codes: E78.0, E78.1, E78.3, E78.4, E78.5) aged 25 and older. Joinpoint regression analysis calculated age-adjusted mortality rates (AAMR) per 100,000 individuals, annual percentage changes (APC), Average Annual Percent Change (AAPC), and 95% confidence intervals. Results Between 1999 and 2023, stroke and hyperlipidemia caused 241,308 deaths, with AAMRs of 1.38 in 1999 and 7.46 in 2023, an AAPC of + 7.16 (95% CI: 6.66 to 8.52). Adult men had higher AAMRs than women, with increases for both sexes [AAPC: + 7.20 vs. + 7.10; p < 0.001]. Black individuals had the highest AAMRs, followed by Hispanics. AAMR rose for all races, notably for Blacks/African Americans (AAPC: + 8.63%) and adults aged 65 and above (AAPC: + 7.35%). Northeast regions have the highest AAMRs, with the Midwest showing the most significant rise (AAPC: + 7.86%). AAMRs varied by state, from 2.0 in Georgia to 9.43 in Vermont in 2023. Non-metropolitan areas had higher AAMRs (4.31) than metropolitan areas (3.54). Conclusion This analysis reveals significant demographic and racial disparities in Stroke mortality among U.S. adults with Hyperlipidemia, which highlights the urgent need for targeted, equity-focused interventions to address these disparities.
- 10 October 2025
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 15 (1) , 1-13
Open AccessTrends and Disparities in Stroke Mortality Among Adults with Hyperlipidemia in the United States, 1999–2023
Background Stroke is a leading cause of death in the U.S., with mortality trends influenced by hyperlipidemia, a significant risk factor for atherosclerosis and cardiovascular disease that can lead to ischemic stroke. This analysis examines stroke-related mortality in hyperlipidemia among adults aged 25 and older from 1999 to 2023. Methods A retrospective analysis of CDC WONDER investigated trends in mortality from Stroke (ICD codes: I60-I69) among Hyperlipidemia patients (ICD codes: E78.0, E78.1, E78.3, E78.4, E78.5) aged 25 and older. Joinpoint regression analysis calculated age-adjusted mortality rates (AAMR) per 100,000 individuals, annual percentage changes (APC), Average Annual Percent Change (AAPC), and 95% confidence intervals. Results Between 1999 and 2023, stroke and hyperlipidemia caused 241,308 deaths, with AAMRs of 1.38 in 1999 and 7.46 in 2023, an AAPC of + 7.16 (95% CI: 6.66 to 8.52). Adult men had higher AAMRs than women, with increases for both sexes [AAPC: + 7.20 vs. + 7.10; p < 0.001]. Black individuals had the highest AAMRs, followed by Hispanics. AAMR rose for all races, notably for Blacks/African Americans (AAPC: + 8.63%) and adults aged 65 and above (AAPC: + 7.35%). Northeast regions have the highest AAMRs, with the Midwest showing the most significant rise (AAPC: + 7.86%). AAMRs varied by state, from 2.0 in Georgia to 9.43 in Vermont in 2023. Non-metropolitan areas had higher AAMRs (4.31) than metropolitan areas (3.54). Conclusion This analysis reveals significant demographic and racial disparities in Stroke mortality among U.S. adults with Hyperlipidemia, which highlights the urgent need for targeted, equity-focused interventions to address these disparities.
- Open Access
- 6 August 2025
- Published by Elsevier in Journal of Clinical Lipidology
WITHDRAWN: Updated meta-analysis of the lipid-lowering efficacy of Obicetrapib: A comprehensive review of randomized controlled trials
- 6 August 2025
- Published by Elsevier in Journal of Clinical Lipidology
Open AccessWITHDRAWN: Updated meta-analysis of the lipid-lowering efficacy of Obicetrapib: A comprehensive review of randomized controlled trials
- Open Access
- 2 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1622
Thyroid Hormone Therapy for Potential Heart Donors: A Comprehensive Review of Clinical Trials
Background: Due to neurohormonal disturbances that occur following brain death, thyroid hormone therapy has been proposed as a means to enhance cardiac function in brain-dead organ donors. However, it remains unclear whether thyroid hormone administration improves clinical outcomes in potential heart donors. Methods: A comprehensive review of clinical trials was conducted to evaluate the impact of thyroid hormone therapy on heart viability and transplantation outcomes. A total of nine randomized controlled trials (RCTs) involving 1189 potential heart donors were included. Results: Thyroid hormone supplementation effectively restored circulating thyroid hormone levels in brain-dead donors. However, findings regarding improvements in cardiac function and transplantation outcomes were inconsistent across studies. While some RCTs reported marginal improvements in hemodynamic parameters and heart transplant viability, these results were not consistently replicated. Furthermore, most studies did not demonstrate a significant enhancement in recipient survival or graft function associated with thyroid hormone therapy. Conclusion: Although thyroid hormone therapy restores thyroid hormone levels in brain-dead donors, current evidence does not consistently support its effectiveness in improving donor heart viability or recipient outcomes. Further research is necessary to clarify the role of thyroid hormone therapy in donor management and its impact on long-term transplant success.
- 2 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1622
Open AccessThyroid Hormone Therapy for Potential Heart Donors: A Comprehensive Review of Clinical Trials
Background: Due to neurohormonal disturbances that occur following brain death, thyroid hormone therapy has been proposed as a means to enhance cardiac function in brain-dead organ donors. However, it remains unclear whether thyroid hormone administration improves clinical outcomes in potential heart donors. Methods: A comprehensive review of clinical trials was conducted to evaluate the impact of thyroid hormone therapy on heart viability and transplantation outcomes. A total of nine randomized controlled trials (RCTs) involving 1189 potential heart donors were included. Results: Thyroid hormone supplementation effectively restored circulating thyroid hormone levels in brain-dead donors. However, findings regarding improvements in cardiac function and transplantation outcomes were inconsistent across studies. While some RCTs reported marginal improvements in hemodynamic parameters and heart transplant viability, these results were not consistently replicated. Furthermore, most studies did not demonstrate a significant enhancement in recipient survival or graft function associated with thyroid hormone therapy. Conclusion: Although thyroid hormone therapy restores thyroid hormone levels in brain-dead donors, current evidence does not consistently support its effectiveness in improving donor heart viability or recipient outcomes. Further research is necessary to clarify the role of thyroid hormone therapy in donor management and its impact on long-term transplant success.